• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Jiang Chang-Jen claimed ownership of 5,949 shares

    11/15/21 12:24:30 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Jiang Chang-Jen

    (Last) (First) (Middle)
    44370 OLD WARM SPRINGS BLVD.

    (Street)
    FREMONT, CA 94538

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/02/2021
    3. Issuer Name and Ticker or Trading Symbol
    ABVC BIOPHARMA, INC. [ ABVC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 5,949 I See Footnote(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Dr. Chang-Jen Jiang holds 1,343 shares of common stock in the Company through his ownership in BioFirst, 6 shares of the Company's common stock through Rgene, and the rest of 4,600 shares through direct ownership.
    /s/ Chang-Jen Jiang 11/15/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ABVC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABVC
    SEC Filings

    See more
    • Amendment: ABVC BioPharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

      5/14/25 4:30:10 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: ABVC BioPharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

      5/14/25 8:30:35 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: ABVC BioPharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

      5/6/25 4:30:28 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    Leadership Updates

    Live Leadership Updates

    See more
    • ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

      FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M. The Licensed Products for MDD and ADHD, owned by ABVC and its su

      11/16/23 10:05:12 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

      FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam) as the new Chief Executive Officer (CEO). Dr. Uttam is very familiar with ABVC and their subsidiaries, because of his role as Chief Operating Officer & Chief Scientific Officer of BioKey, Inc., a GMP-certified facility owned by ABVC that provides its clients with integrated pharmaceutical services, including early-phase product development, formulation development, analytical development & d

      6/26/23 8:30:00 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Jiang Shuling claimed ownership of 7,908,805 shares

      3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)

      7/12/22 5:01:09 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider An Chihliang claimed ownership of 13,334 shares

      3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)

      3/31/22 11:31:22 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Sakamoto Norimi

      3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)

      12/10/21 4:19:06 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

      SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

      11/14/24 7:33:18 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ABVC BioPharma Inc. (Amendment)

      SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

      2/13/24 7:59:14 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ABVC BioPharma Inc.

      SC 13G - ABVC BIOPHARMA, INC. (0001173313) (Subject)

      8/7/23 4:01:26 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ABVC
    Financials

    Live finance-specific insights

    See more
    • ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

      FREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced in response to the discontinuation of Prozac[1] due to increasing concerns around side effects, ABVC believes its ABV-1504, which has the API, "Radix Polygala", known as Polygala tenuifolia Willd or PDC-1421, can fill this void in the mental health market. With a robust formulation designed to reduce adverse effects, PDC-1421 promises to offer a safer and more effective solution for patients dealing with MDD and ADHD[2]. ABVC's ABV-1504 has c

      12/19/24 8:30:00 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

      FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. ("OncoX") as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and R

      12/11/24 6:30:00 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

      ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in incomeReceived Cash Milestone Incomes of $496,000 for the nine months ended September 30, 2024 FREMONT, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the third quarter ended September 30, 2024. Key Financial and Operational Highl

      11/14/24 9:00:00 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

      FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pha

      2/8/24 9:17:05 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care